Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9 Neoplasms 6 Ovarian Neoplasms 3 Uterine Cervical Neoplasms 1 Solid Tumors 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Patients With Any Advanced Solid Tumors 1 Malignant Solid Tumour 1 Leukemia, Myeloid, Acute 1 Genital Neoplasms, Female 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Paclitaxel 12 Gemcitabine 9 atezolizumab 8 Carboplatin 8 Bevacizumab 6 tocilizumab 4 navitoclax 4 liposomal doxorubicin 4 Irinotecan 4 Erlotinib Hydrochloride 4 Cetuximab 4 Sunitinib 3 Oxaliplatin 3 Leucovorin 3 Injections 3 Fluorouracil 3 Docetaxel 3 Cyclophosphamide 3 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 tislelizumab 2 temsirolimus 2 ridaforolimus 2 plocabulin 2 pembrolizumab 2 pazopanib 2 olaparib 2 obinutuzumab 2 linifanib 2 fludarabine 2 envafolimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Solid Tumors × nintedanib × Clear all

NCT01349296 2016-05-20

BARIS

University of Cologne

Phase 1 Completed

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡